en.Wedoany.com Reported - Mexico has recently bolstered domestic pharmaceutical production through industrial policies and public procurement, attracting investments to reduce dependence on imported drugs. This strategy positions healthcare as a dual engine for public health and economic development.

Healthcare resilience depends not only on hospital capacity and emergency preparedness but increasingly on the strength of domestic manufacturing, supply chains, and innovation ecosystems. Mexico's evolving strategy links healthcare security with industrial competitiveness, creating new opportunities for investment and long-term industry growth. In the field of rare diseases, David López of Recordati Rare Diseases noted that patients with rare conditions require a coordinated care model integrating specialists, diagnostics, mental health support, and long-term monitoring. Multidisciplinary care is becoming a key component of patient-centered treatment strategies.

In terms of artificial intelligence applications, Waleed Mohsen of Verbal stated that AI is emerging as a strategic tool to address trust issues in healthcare. This technology can be used to enhance claims management transparency, improve patient engagement, and strengthen data integrity, thereby going beyond mere efficiency gains to achieve more reliable healthcare interactions.

Mexico's pharmaceutical sovereignty strategy continues to attract substantial private sector investment. Recent commitments from pharmaceutical companies exceeding 21 billion pesos reflect growing confidence in the country's healthcare manufacturing ecosystem. These investments cover areas such as capacity expansion, research, technology transfer, and vaccine development, aiming to support supply security and economic growth objectives.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com